{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021219","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.891311+00:00","generated_at":"2026-06-22T14:45:44.537625+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcus Biosciences Q3 net loss narrows to $64.9M, cash $1.19B, ARC-10 amended to compare domvanalimab vs pembro","bullets":["Q3 revenue $33.6M (up from $9.5M); net loss $64.9M vs $78.0M prior year.","Cash and securities $1.19B as of Sep 30, 2022, funding operations into 2026.","ARC-10 Phase 3 amended: domvanalimab+zimberelimab vs pembrolizumab, no chemo arm, OS primary endpoint, n=600.","ARC-7 topline data on track for Q4 2022; presentation planned at 2023 medical conference.","Initiated ARC-20 Phase 1/1b for HIF-2a inhibitor AB521 in cancer patients."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021219","json":"https://secwatch.observer/filing/0000950170-22-021219.json","markdown":"https://secwatch.observer/filing/0000950170-22-021219.md","text":"https://secwatch.observer/filing/0000950170-22-021219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022021219/0000950170-22-021219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022021219/rcus-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T14:45:44.537625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c67a0b06045460aa06d8180af021de4f07aeeefd","claim":"Arcus Biosciences, Inc. reported financial results for the three and nine months ended September 30, 2022.","evidence_excerpt":"On November 2, 2022, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022021219/0000950170-22-021219-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}